Advanced Search
Contact | Corporate | Help

A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG)

Sponsors:
  • Genentech
  • Roche Pharma AG
Phases:
  • Phase III
IndicationsAcronym:
BELONG
  • Lupus Nephritis
  • Systemic Lupus Erythematosus
Age Groups:
  • Child
  • Adult
  • Senior
Gender:
Both
Names:
  • Drug: corticosteroids
  • Drug: cyclophosphamide
  • Drug: mycophenolate mofetil
  • Drug: ocrelizumab
  • Drug: placebo
Enrollment:
369

Additional information about NCT00626197.


SourceSolution © 2008-2012